Aktive Positionen von Tomas Hode
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Direktor/Vorstandsmitglied | 01.01.2009 | - |
Gründer | 01.01.2009 | - | |
Präsident | - | - | |
Vorstandsvorsitzender | 01.01.2009 | - | |
Missouri Biotechnology Association | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Tomas Hode
Ausbildung von Tomas Hode
University of Stockholm | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 3 |
Schweden | 2 |
Operativ
Director/Board Member | 2 |
Chief Executive Officer | 1 |
Founder | 1 |
Sektoral
Health Technology | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Health Technology |
Missouri Biotechnology Association |
- Börse
- Insiders
- Tomas Hode
- Erfahrung